 Carlton Barnett
Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonic Neoplasms | 5 | 2020 | 243 | 1.990 |
Why?
| | Pancreatic Neoplasms | 10 | 2013 | 882 | 1.880 |
Why?
| | Intercellular Adhesion Molecule-1 | 7 | 2013 | 135 | 1.580 |
Why?
| | Adenocarcinoma | 8 | 2020 | 898 | 1.500 |
Why?
| | Erythrocyte Transfusion | 6 | 2013 | 181 | 1.430 |
Why?
| | Liver Neoplasms | 6 | 2020 | 640 | 1.410 |
Why?
| | Neutrophils | 13 | 2017 | 1205 | 1.250 |
Why?
| | Plasma | 4 | 2013 | 206 | 1.080 |
Why?
| | Hyperthermia, Induced | 3 | 2021 | 109 | 0.900 |
Why?
| | Cytokines | 4 | 2013 | 2017 | 0.700 |
Why?
| | Tumor Microenvironment | 3 | 2020 | 634 | 0.700 |
Why?
| | Burns, Electric | 1 | 2020 | 26 | 0.700 |
Why?
| | Microwaves | 2 | 2019 | 35 | 0.680 |
Why?
| | Transfusion Reaction | 2 | 2010 | 43 | 0.680 |
Why?
| | Kidney Neoplasms | 1 | 2021 | 350 | 0.560 |
Why?
| | Blood Preservation | 2 | 2012 | 271 | 0.560 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 964 | 0.550 |
Why?
| | Liver | 2 | 2020 | 1839 | 0.550 |
Why?
| | Surgical Flaps | 2 | 2016 | 135 | 0.530 |
Why?
| | Macrophages | 4 | 2013 | 1480 | 0.530 |
Why?
| | Ileocecal Valve | 1 | 2016 | 4 | 0.520 |
Why?
| | Organ Sparing Treatments | 1 | 2016 | 32 | 0.510 |
Why?
| | Colectomy | 1 | 2016 | 94 | 0.490 |
Why?
| | Pancreaticojejunostomy | 1 | 2015 | 8 | 0.480 |
Why?
| | Duodenum | 1 | 2015 | 75 | 0.460 |
Why?
| | Multiple Organ Failure | 5 | 2011 | 122 | 0.440 |
Why?
| | Blood Substitutes | 1 | 2013 | 24 | 0.410 |
Why?
| | Disease Progression | 6 | 2020 | 2635 | 0.400 |
Why?
| | Crohn Disease | 1 | 2016 | 217 | 0.400 |
Why?
| | Pancreas | 1 | 2015 | 306 | 0.400 |
Why?
| | Neoplasm Metastasis | 3 | 2013 | 610 | 0.390 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2020 | 530 | 0.390 |
Why?
| | Blood Loss, Surgical | 2 | 2010 | 93 | 0.380 |
Why?
| | Hematocrit | 1 | 2012 | 93 | 0.380 |
Why?
| | Cell Line, Tumor | 6 | 2020 | 3215 | 0.370 |
Why?
| | Mice | 12 | 2020 | 16937 | 0.360 |
Why?
| | Hemoglobins | 1 | 2013 | 339 | 0.350 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 613 | 0.350 |
Why?
| | Hernia, Abdominal | 1 | 2010 | 7 | 0.340 |
Why?
| | Peritoneum | 1 | 2010 | 41 | 0.340 |
Why?
| | Osteomyelitis | 2 | 2009 | 122 | 0.340 |
Why?
| | Interleukin-6 | 5 | 1996 | 720 | 0.340 |
Why?
| | Surgical Mesh | 1 | 2010 | 46 | 0.330 |
Why?
| | Blood Component Transfusion | 1 | 2010 | 82 | 0.330 |
Why?
| | Hepatectomy | 2 | 2008 | 212 | 0.320 |
Why?
| | Hemipelvectomy | 1 | 2008 | 2 | 0.310 |
Why?
| | Pancreaticoduodenectomy | 1 | 2010 | 159 | 0.310 |
Why?
| | Blood Platelets | 2 | 2012 | 380 | 0.310 |
Why?
| | Pressure Ulcer | 1 | 2008 | 34 | 0.300 |
Why?
| | Neoplasms | 2 | 2017 | 2470 | 0.300 |
Why?
| | Fires | 2 | 2019 | 88 | 0.300 |
Why?
| | Operating Rooms | 2 | 2019 | 115 | 0.290 |
Why?
| | Mice, Inbred C57BL | 5 | 2020 | 5440 | 0.290 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2010 | 211 | 0.290 |
Why?
| | Colorectal Neoplasms | 1 | 2015 | 752 | 0.290 |
Why?
| | Animals | 17 | 2020 | 35361 | 0.280 |
Why?
| | Platelet Transfusion | 1 | 2008 | 59 | 0.280 |
Why?
| | Critical Care | 1 | 2012 | 553 | 0.270 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 297 | 0.260 |
Why?
| | Laparoscopy | 2 | 2010 | 451 | 0.250 |
Why?
| | Critical Illness | 1 | 2012 | 758 | 0.250 |
Why?
| | Neoplasm Invasiveness | 4 | 2013 | 485 | 0.250 |
Why?
| | Macrophage Activation | 2 | 2020 | 189 | 0.250 |
Why?
| | Teaching | 1 | 2008 | 214 | 0.250 |
Why?
| | Sex Characteristics | 1 | 2010 | 737 | 0.240 |
Why?
| | Humans | 41 | 2021 | 129650 | 0.230 |
Why?
| | Superoxides | 5 | 1998 | 201 | 0.210 |
Why?
| | Disease Models, Animal | 4 | 2020 | 4063 | 0.210 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2001 | 84 | 0.210 |
Why?
| | Platelet Activating Factor | 4 | 1999 | 75 | 0.200 |
Why?
| | Wounds and Injuries | 3 | 2012 | 711 | 0.200 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2001 | 272 | 0.190 |
Why?
| | Neoplasm Transplantation | 2 | 2020 | 257 | 0.180 |
Why?
| | Phospholipases A | 1 | 2001 | 99 | 0.180 |
Why?
| | Catheter Ablation | 2 | 2001 | 335 | 0.180 |
Why?
| | Arginase | 1 | 2020 | 32 | 0.170 |
Why?
| | Perioperative Care | 1 | 2021 | 152 | 0.170 |
Why?
| | Leukocyte Elastase | 2 | 1997 | 74 | 0.170 |
Why?
| | Immunocompetence | 1 | 2019 | 44 | 0.160 |
Why?
| | Aftercare | 1 | 2021 | 205 | 0.160 |
Why?
| | Electrosurgery | 1 | 2019 | 44 | 0.160 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2019 | 18 | 0.160 |
Why?
| | Thoracic Injuries | 1 | 1999 | 55 | 0.160 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 303 | 0.150 |
Why?
| | Wearable Electronic Devices | 1 | 2019 | 45 | 0.150 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 274 | 0.150 |
Why?
| | Ethanol | 2 | 2019 | 589 | 0.150 |
Why?
| | CD18 Antigens | 1 | 1998 | 26 | 0.150 |
Why?
| | Apoptosis | 3 | 1996 | 2503 | 0.150 |
Why?
| | Smoke | 1 | 2019 | 140 | 0.150 |
Why?
| | Internship and Residency | 1 | 2008 | 1053 | 0.150 |
Why?
| | Lymphatic Metastasis | 2 | 2010 | 320 | 0.150 |
Why?
| | Endopeptidases | 1 | 1998 | 87 | 0.150 |
Why?
| | Injury Severity Score | 3 | 2015 | 509 | 0.140 |
Why?
| | Pancreatic Elastase | 2 | 1999 | 60 | 0.140 |
Why?
| | Peritoneal Neoplasms | 2 | 2010 | 87 | 0.140 |
Why?
| | Carbon Dioxide | 1 | 2019 | 260 | 0.140 |
Why?
| | Sex Factors | 2 | 2015 | 1968 | 0.140 |
Why?
| | Isoproterenol | 1 | 1997 | 115 | 0.140 |
Why?
| | Hemostasis, Surgical | 2 | 2008 | 22 | 0.130 |
Why?
| | General Surgery | 2 | 2009 | 152 | 0.130 |
Why?
| | Surgical Procedures, Operative | 1 | 2019 | 244 | 0.130 |
Why?
| | Female | 17 | 2019 | 68776 | 0.130 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1997 | 127 | 0.130 |
Why?
| | Adrenergic beta-Agonists | 1 | 1997 | 132 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 1999 | 505 | 0.130 |
Why?
| | Cell Death | 1 | 1998 | 354 | 0.130 |
Why?
| | Patient Care Team | 1 | 2021 | 605 | 0.130 |
Why?
| | Breast Neoplasms | 1 | 2008 | 2142 | 0.130 |
Why?
| | Calcium | 2 | 2001 | 1213 | 0.120 |
Why?
| | Erythrocytes | 2 | 2012 | 672 | 0.120 |
Why?
| | Interleukin-8 | 1 | 1996 | 262 | 0.120 |
Why?
| | Chimerism | 1 | 2015 | 31 | 0.120 |
Why?
| | Recovery of Function | 1 | 2019 | 642 | 0.120 |
Why?
| | Down-Regulation | 2 | 2013 | 636 | 0.120 |
Why?
| | Patient Discharge | 1 | 2021 | 857 | 0.120 |
Why?
| | Parity | 1 | 2015 | 120 | 0.120 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2008 | 375 | 0.120 |
Why?
| | Skin | 1 | 2019 | 725 | 0.120 |
Why?
| | Male | 16 | 2019 | 63681 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2019 | 10230 | 0.110 |
Why?
| | Adult | 12 | 2016 | 35576 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2013 | 35 | 0.100 |
Why?
| | In Vitro Techniques | 2 | 2010 | 1085 | 0.100 |
Why?
| | Physicians | 1 | 2021 | 865 | 0.100 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 43 | 0.100 |
Why?
| | Protein Array Analysis | 1 | 2013 | 56 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2012 | 1198 | 0.100 |
Why?
| | Survival Rate | 2 | 2015 | 1877 | 0.100 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 171 | 0.100 |
Why?
| | Tumor Cells, Cultured | 2 | 2012 | 940 | 0.100 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2012 | 89 | 0.090 |
Why?
| | Stromal Cells | 1 | 2012 | 107 | 0.090 |
Why?
| | Chemokine CCL2 | 1 | 2012 | 118 | 0.090 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 587 | 0.090 |
Why?
| | Neoplasms, Experimental | 1 | 2012 | 171 | 0.090 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 516 | 0.090 |
Why?
| | Perioperative Period | 1 | 2010 | 49 | 0.090 |
Why?
| | Blood Transfusion, Autologous | 1 | 2010 | 16 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2010 | 201 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2013 | 1288 | 0.080 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2010 | 71 | 0.080 |
Why?
| | Linear Models | 1 | 2012 | 819 | 0.080 |
Why?
| | Immunomodulation | 1 | 2010 | 93 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 833 | 0.080 |
Why?
| | Tetradecanoylphorbol Acetate | 3 | 1999 | 149 | 0.080 |
Why?
| | Academic Medical Centers | 1 | 2012 | 481 | 0.080 |
Why?
| | Thrombocytopenia | 1 | 2011 | 186 | 0.080 |
Why?
| | DNA Primers | 1 | 2010 | 510 | 0.080 |
Why?
| | Signal Transduction | 3 | 2020 | 4925 | 0.070 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2008 | 24 | 0.070 |
Why?
| | Ligation | 1 | 2008 | 87 | 0.070 |
Why?
| | Hepatic Veins | 1 | 2008 | 31 | 0.070 |
Why?
| | Hepatic Artery | 1 | 2008 | 59 | 0.070 |
Why?
| | RNA, Messenger | 2 | 2013 | 2708 | 0.070 |
Why?
| | Cholecystectomy | 1 | 2008 | 59 | 0.070 |
Why?
| | Time Factors | 4 | 2012 | 6556 | 0.070 |
Why?
| | Aged | 7 | 2019 | 22103 | 0.070 |
Why?
| | CHO Cells | 2 | 1998 | 153 | 0.070 |
Why?
| | Middle Aged | 9 | 2019 | 31154 | 0.070 |
Why?
| | Cricetinae | 2 | 1998 | 277 | 0.070 |
Why?
| | Swine | 2 | 2019 | 760 | 0.070 |
Why?
| | Pelvic Bones | 1 | 2009 | 156 | 0.070 |
Why?
| | Base Sequence | 1 | 2010 | 2142 | 0.060 |
Why?
| | Safety | 1 | 2008 | 331 | 0.060 |
Why?
| | Body Weight | 1 | 2010 | 940 | 0.060 |
Why?
| | Cell Movement | 1 | 2010 | 945 | 0.060 |
Why?
| | Preoperative Care | 1 | 2008 | 340 | 0.060 |
Why?
| | Education, Medical | 1 | 2009 | 244 | 0.060 |
Why?
| | Surgical Stapling | 1 | 2005 | 14 | 0.060 |
Why?
| | Follow-Up Studies | 3 | 2009 | 4897 | 0.060 |
Why?
| | Immediate-Early Proteins | 1 | 2005 | 52 | 0.060 |
Why?
| | Prognosis | 2 | 2010 | 3794 | 0.060 |
Why?
| | Cytosol | 2 | 2001 | 218 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2010 | 2871 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2391 | 0.050 |
Why?
| | Endothelium, Vascular | 2 | 2001 | 901 | 0.050 |
Why?
| | Retrospective Studies | 6 | 2021 | 14518 | 0.050 |
Why?
| | Cells, Cultured | 4 | 1997 | 4083 | 0.050 |
Why?
| | Adrenalectomy | 1 | 2001 | 67 | 0.050 |
Why?
| | Injections, Intralesional | 1 | 2001 | 34 | 0.050 |
Why?
| | Egtazic Acid | 1 | 2001 | 41 | 0.050 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2001 | 48 | 0.050 |
Why?
| | Umbilical Veins | 1 | 2001 | 61 | 0.050 |
Why?
| | Chelating Agents | 1 | 2001 | 68 | 0.050 |
Why?
| | Risk Factors | 5 | 2021 | 9765 | 0.050 |
Why?
| | Pilot Projects | 2 | 2019 | 1587 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2012 | 5066 | 0.040 |
Why?
| | Cryosurgery | 1 | 2001 | 57 | 0.040 |
Why?
| | Hospitals, Veterans | 1 | 2021 | 255 | 0.040 |
Why?
| | Prospective Studies | 3 | 2021 | 7133 | 0.040 |
Why?
| | Sialoglycoproteins | 1 | 1999 | 155 | 0.040 |
Why?
| | 2-Propanol | 1 | 2019 | 22 | 0.040 |
Why?
| | Chlorhexidine | 1 | 2019 | 24 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 1999 | 161 | 0.040 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 1999 | 85 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2005 | 1356 | 0.040 |
Why?
| | Receptors, Interleukin-1 | 1 | 1999 | 218 | 0.040 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1999 | 252 | 0.040 |
Why?
| | CD11 Antigens | 1 | 1998 | 30 | 0.040 |
Why?
| | Up-Regulation | 1 | 2001 | 840 | 0.040 |
Why?
| | Postoperative Period | 1 | 2019 | 329 | 0.040 |
Why?
| | Equipment Design | 1 | 2019 | 514 | 0.040 |
Why?
| | Models, Animal | 1 | 2019 | 376 | 0.040 |
Why?
| | Lipopolysaccharides | 1 | 2001 | 875 | 0.040 |
Why?
| | Microscopy, Electron | 1 | 1998 | 426 | 0.040 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 1 | 1997 | 55 | 0.040 |
Why?
| | Colforsin | 1 | 1997 | 50 | 0.040 |
Why?
| | Protease Inhibitors | 1 | 1998 | 106 | 0.040 |
Why?
| | United States Department of Veterans Affairs | 1 | 2021 | 635 | 0.030 |
Why?
| | Cardiopulmonary Bypass | 1 | 1999 | 202 | 0.030 |
Why?
| | Cross-Linking Reagents | 1 | 1998 | 205 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 3 | 2001 | 2535 | 0.030 |
Why?
| | Cell Adhesion | 1 | 1998 | 452 | 0.030 |
Why?
| | Walking | 1 | 2021 | 501 | 0.030 |
Why?
| | Ultrafiltration | 1 | 1996 | 28 | 0.030 |
Why?
| | Risk Assessment | 2 | 2021 | 3240 | 0.030 |
Why?
| | Chromatography, Affinity | 1 | 1996 | 83 | 0.030 |
Why?
| | Transfection | 1 | 1998 | 911 | 0.030 |
Why?
| | Awards and Prizes | 1 | 1996 | 63 | 0.030 |
Why?
| | Patient Readmission | 1 | 2021 | 667 | 0.030 |
Why?
| | Cell Line | 1 | 2001 | 2781 | 0.030 |
Why?
| | Substrate Specificity | 1 | 1996 | 368 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 1996 | 2058 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1996 | 220 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 1996 | 2832 | 0.030 |
Why?
| | Quality Improvement | 1 | 2021 | 1103 | 0.030 |
Why?
| | Disease-Free Survival | 2 | 2007 | 648 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1304 | 0.030 |
Why?
| | Neoplasm Staging | 2 | 2007 | 1295 | 0.030 |
Why?
| | Blood Group Incompatibility | 1 | 2012 | 11 | 0.030 |
Why?
| | Exsanguination | 1 | 2012 | 19 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 1998 | 1367 | 0.020 |
Why?
| | Registries | 2 | 2012 | 1896 | 0.020 |
Why?
| | Hypotension | 1 | 2012 | 116 | 0.020 |
Why?
| | Platelet Count | 1 | 2011 | 82 | 0.020 |
Why?
| | Inflammation | 3 | 1996 | 2736 | 0.020 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 167 | 0.020 |
Why?
| | Shock, Hemorrhagic | 1 | 2012 | 165 | 0.020 |
Why?
| | Adolescent | 3 | 2012 | 20393 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2021 | 2483 | 0.020 |
Why?
| | Models, Biological | 1 | 1996 | 1722 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2000 | 3408 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 1023 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2012 | 613 | 0.020 |
Why?
| | NADPH Oxidases | 2 | 1999 | 108 | 0.020 |
Why?
| | Brain Injuries | 1 | 2012 | 468 | 0.020 |
Why?
| | Length of Stay | 1 | 2012 | 1127 | 0.020 |
Why?
| | Career Choice | 1 | 2009 | 207 | 0.020 |
Why?
| | Lymph Node Excision | 1 | 2007 | 164 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2009 | 7086 | 0.020 |
Why?
| | Logistic Models | 1 | 2011 | 1988 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 1952 | 0.020 |
Why?
| | Cysteine-Rich Protein 61 | 1 | 2005 | 5 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 2005 | 173 | 0.010 |
Why?
| | Antibodies, Neoplasm | 1 | 2005 | 35 | 0.010 |
Why?
| | RNA, Neoplasm | 1 | 2005 | 88 | 0.010 |
Why?
| | United States | 1 | 2021 | 13903 | 0.010 |
Why?
| | Survival Analysis | 1 | 2007 | 1274 | 0.010 |
Why?
| | Ultrasonography, Interventional | 1 | 2005 | 128 | 0.010 |
Why?
| | Extracellular Matrix Proteins | 1 | 2005 | 144 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2005 | 482 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 3144 | 0.010 |
Why?
| | Mice, Nude | 1 | 2005 | 683 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 958 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2005 | 1698 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1838 | 0.010 |
Why?
| | Infant | 1 | 2012 | 9024 | 0.010 |
Why?
| | Child, Preschool | 1 | 2012 | 10517 | 0.010 |
Why?
| | Quality of Life | 1 | 2009 | 2704 | 0.010 |
Why?
| | Patient Selection | 1 | 2001 | 663 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 1999 | 596 | 0.010 |
Why?
| | Chromatography, Thin Layer | 1 | 1996 | 23 | 0.010 |
Why?
| | Stimulation, Chemical | 1 | 1996 | 63 | 0.010 |
Why?
| | Neutrophil Activation | 1 | 1996 | 79 | 0.010 |
Why?
| | Enzyme Activation | 1 | 1996 | 811 | 0.010 |
Why?
| | Child | 1 | 2012 | 20883 | 0.010 |
Why?
| | Lipids | 1 | 1996 | 625 | 0.010 |
Why?
|
|
Barnett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|